AZ chief Pascal Soriot says Crestor freefall could slow in H2 by Angus Liu Friday, May 18, 2018 Crestor sales nosedived by 42% to $389 million in Q1, well below analyst estimates, but execs hope new cancer drugs can cushion the fall.
Vermont thumbs its nose at Trump with drug import bill by Eric Sagonowsky Thursday, May 17, 2018 Vermont lawmakers took it upon themselves to pass a bill allowing drug imports from Canada. The catch? It'll need an OK from the Trump administration.
Takeda executives expect Velcade sales to plummet 30% by Angus Liu Monday, May 14, 2018 Takeda expects Velcade sales to drop more than 30% this year, but it's hoping newer drugs Ninlanro and Entyvio help fill the gap.
Top 10 best-selling drugs by 25 years of U.S. sales by Angus Liu Monday, May 14, 2018 What's notable about the 10 best-selling drugs over the past 25 years? Here's a hint: Today's king is passing, and the next has a long life ahead.
Bayer's growth-driving quintet? Better make that a trio by Angus Liu Thursday, May 3, 2018 A strong euro doesn't explain away Bayer's consumer health stall—or the low turnout for key cancer meds Xofigo and Stivarga.
At Novo Nordisk, the future's all about GLP-1s by Angus Liu Wednesday, May 2, 2018 Novo's Victoza lost share—again—but classwide growth boosted sales, and with doctor feedback strong for Ozempic, GLP-1 gains are ahead, analysts say.
New Gilead rival takes a bite out of Glaxo's HIV growth by Angus Liu Friday, April 27, 2018 GSK execs lauded their HIV drugs Triumeq and Tivicay this week, but both fell short of forecasts—thanks to Gilead's new Biktarvy, analysts say.
